tisotumab vedotin + carboplatin

Tisotumab vedotin + carboplatin is an investigational combination regimen used in oncology clinical trials, most notably as a frontline treatment for recurrent or metastatic cervical cancer. **Tisotumab vedotin** is an antibody-drug conjugate targeting tissue factor, delivering a cell-killing agent to cells that express this protein. **Carboplatin** is a platinum-based chemotherapy agent that binds and damages DNA, leading to cell death[1][3][7]. The combination was shown in phase 1/2 studies (e.g., innovaTV 205, NCT03786081) to have a promising objective response rate and manageable safety profile in cervical cancer. This combination is not an approved, branded product but is under investigation, especially as first-line therapy in recurrent/metastatic cervical cancer[1][3][5][7].

Other names

tisotumab vedotin and carboplatin